These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23780836)

  • 21. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
    Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
    Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum chromogranin A in patients with hepatocellular carcinoma.
    Leone N; Pellicano R; Brunello F; Rizzetto M; Ponzetto A
    Clin Exp Med; 2002 Nov; 2(3):119-23. PubMed ID: 12447608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
    Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
    Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.
    Poon RT; Ho JW; Tong CS; Lau C; Ng IO; Fan ST
    Br J Surg; 2004 Oct; 91(10):1354-60. PubMed ID: 15376182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum tissue polypeptide specific antigen as a noninvasive prognostic indicator for early recurrence of hepatocellular carcinoma after curative resection.
    Yao WJ; Wang ST; Chow NH; Chang TT; Lin PW; Tu DG
    Cancer; 2002 Jul; 95(1):112-8. PubMed ID: 12115324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
    Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy.
    Kaibori M; Ishizaki M; Matsui K; Kwon AH
    Am J Surg; 2012 Sep; 204(3):300-7. PubMed ID: 22591698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
    Kobayashi M; Ikeda K; Kawamura Y; Yatsuji H; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Cancer; 2009 Feb; 115(3):571-80. PubMed ID: 19117347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.
    Ikeda K; Saitoh S; Koida I; Arase Y; Tsubota A; Chayama K; Kumada H; Kawanishi M
    Hepatology; 1993 Jul; 18(1):47-53. PubMed ID: 7686879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is serum endocan a sensitive biomarker for early recurrence of hepatocellular carcinoma after radiofrequency ablation?
    Omar SA; Attia NM; Sheir MI; Amer AS; El Shabrawy MM; Hasan BB
    Eur J Gastroenterol Hepatol; 2021 Jul; 33(7):1015-1022. PubMed ID: 33867440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
    Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
    Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma.
    Sun HC; Zhang W; Qin LX; Zhang BH; Ye QH; Wang L; Ren N; Zhuang PY; Zhu XD; Fan J; Tang ZY
    J Hepatol; 2007 Nov; 47(5):684-90. PubMed ID: 17854945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein.
    Sato Y; Nakata K; Kato Y; Shima M; Ishii N; Koji T; Taketa K; Endo Y; Nagataki S
    N Engl J Med; 1993 Jun; 328(25):1802-6. PubMed ID: 7684823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies.
    Voumvouraki A; Notas G; Koulentaki M; Georgiadou M; Klironomos S; Kouroumalis E
    Eur J Clin Invest; 2012 Aug; 42(8):815-22. PubMed ID: 22304651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
    Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
    J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis.
    Verhelst X; Vanderschaeghe D; Castéra L; Raes T; Geerts A; Francoz C; Colman R; Durand F; Callewaert N; Van Vlierberghe H
    Clin Cancer Res; 2017 Jun; 23(11):2750-2758. PubMed ID: 27986746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.